Krieger G, Kehl A, Wander H E, Salo A M, Rauschecker H F, Nagel G A
Int J Cancer. 1983 Feb 15;31(2):207-11. doi: 10.1002/ijc.2910310212.
Serum circulating immune complexes (CIC) were repeatedly measured by means of the CIq binding assay (Cba) and the Raji cell assay (Rca) in 158 patients with metastatic breast cancer (mbc). Frequency of occurrence and levels of CIC were only slightly increased in mbc when compared to age-matched healthy women. They were identical to those of patients with localized breast cancer prior to mastectomy and to those of post mastectomy patients without evidence of recurrent disease. In mbc the results of the Cba and the Rca showed a poor correlation, whereas in a control group of patients with rheumatoid arthritis both tests showed significantly elevated levels of CIC. Patients with mbc were followed up clinically and biochemically by serially measuring CIC for an average of 10 months. Patients with positive CIC did not prove to be an unfavorable group regarding progression of disease and response to chemotherapy. When CEA and CIC levels were compared, CIC, unlike CEA, was a poor tumor marker. In conclusion, CIC as measured by CIq binding assay and Raji cell assay are not clinically significant tumor markers or prognostic indicators in patients with metastatic breast cancer.
采用Clq结合试验（Cba）和Raji细胞试验（Rca）对158例转移性乳腺癌（mbc）患者的血清循环免疫复合物（CIC）进行了多次检测。与年龄匹配的健康女性相比，mbc患者中CIC的发生率和水平仅略有升高。它们与乳房切除术前行局限性乳腺癌患者以及乳房切除术后无疾病复发证据患者的CIC发生率和水平相同。在mbc中，Cba和Rca的结果显示相关性较差，而在类风湿性关节炎患者对照组中，两种检测均显示CIC水平显著升高。对mbc患者进行了临床和生化随访，连续检测CIC平均达10个月。CIC呈阳性的患者在疾病进展和化疗反应方面并非预后不良组。当比较CEA和CIC水平时，与CEA不同，CIC是一种较差的肿瘤标志物。总之，通过Clq结合试验和Raji细胞试验检测的CIC在转移性乳腺癌患者中并非具有临床意义的肿瘤标志物或预后指标。
